COVID-19 Update

As the global impacts of COVID-19 evolve, Novocure® is taking proactive steps to protect and support the health and well-being of our colleagues, our patients and caregivers, and all of our partners, while we continue to deliver our therapy to patients in need. Learn more.

Treatment for glioblastoma (GBM)
This site is intended for US healthcare professionals only.

Preventing and managing dermatologic adverse events (dAEs)

nCompass™ brochure

Your guide to preventing, identifying, and managing dAEs for patients using Optune to help maximize time on therapy

View this PDF

References: 1. Lacouture ME, Davis ME, Elzinga G, et al. Characterization and management of dermatologic adverse events with the NovoTTF-100A System, a novel anti-mitotic electric field device for the treatment of recurrent glioblastoma. Semin Oncol. 2014;41(3 suppl 4):S1-14. 2. Novocure Data on File OPT-147.
3. Jennings DL II, Sumrall AL, Haggstrom DE. Classification of dermatologic adverse events and management strategies in patients receiving therapy with Optune for high grade gliomas. Poster presented at: 2016 Society for NeuroOncology (SNO) Annual Meeting: November 17-20, 2016; Scottsdale, AZ.

Indications For Use

Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).